Masaaki Shoji
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Number of thrombosed venous segments and clinical outcomes in cancer-associated isolated distal deep vein thrombosis: insights from the ONCO DVT Study.
Journal: Journal of thrombosis and thrombolysis
Published: February 02, 2026
Impact of body weight on clinical outcomes in cancer patients with low-risk pulmonary embolism receiving rivaroxaban: Insights from the ONCO PE trial.
Journal: Thrombosis research
Published: January 22, 2026
Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST) - A Prospective Multicenter Study.
Journal: Circulation journal : official journal of the Japanese Circulation Society
Published: December 03, 2025
Asymptomatic and symptomatic cardiac toxicity associated with immune checkpoint inhibitors: insights from a Japanese registry.
Journal: European heart journal open
Published: September 23, 2025
Feasibility study protocol for the evaluation of home blood pressure in patients receiving angiogenesis inhibitor therapy: a multicenter observational study.
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: August 13, 2025
The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study.
Journal: Thrombosis research
Published: May 06, 2025
Impact of thrombocytopenia in patients with cancer-associated isolated distal deep vein thrombosis treated with edoxaban for 12 months versus 3 months: Insights from the ONCO DVT study.
Journal: Thrombosis research
Published: March 19, 2025
Clinical outcomes of cancer-associated isolated distal deep vein thrombosis: a comparison between asymptomatic and symptomatic thrombosis-findings from the ONCO DVT Study.
Journal: Research and practice in thrombosis and haemostasis
Published: January 19, 2025
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
Journal: Circulation
Published: November 18, 2024
Last Updated: 09/26/2026